Prospective study ofCandida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Stein RS, Kayser J, Flexner JM: Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer 1982, 50: 2247–2251.
Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. American Journal of Medicine 1982, 72: 101–111.
EORTC International Antimicrobial Therapy Cooperative Group: Empiric antifungal therapy in febrile granulocytopenic patients. American Journal of Medicine 1989, 86: 668–672.
Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, Francis P, Weinberger M, Roilides E, Marshall D, Gress J, Pizzo PA: Empiric therapy with amphotericin B in febrile granulocytopenic patients. Reviews of Infectious Diseases 1991, 13: 496–503.
Perfect JR, Pickard WW, Hunt DL, Palmer B, Schell WA: The use of amphotericin B in nosocomial fungal infections. Reviews of Infectious Diseases 1991, 13: 474–479.
Sandford GR, Merz WG, Wingard JR, Charache P, Saral R: The value of fungal surveillance cultures as predictors of systemic fungal infections. Journal of Infectious Diseases 1980, 142: 503–509.
Bodey GP: Fungal infections complicating acute leukemia. Journal of Chronic Diseases 1966, 19: 667–687.
Meunier-Carpentier F, Kiehn TE, Armstrong D: Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. American Journal of Medicine 1981, 71: 363–370.
De Gregorio MW, Lee WMF, Linker CA, Ries CA: Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982, 50: 2780–2784.
Martino P, Girmenia C, Venditti M, Micozzi A, Santilli S, Burgio VL, Mandelli F: Candida colonization and systemic infections in neutropenic patients. Cancer 1989, 64: 2030–2034.
Wingard JR, Merz WG, Saral R:Candida tropicalis: a major pathogen in immunocompromised patients. Annals of Internal Medicine 1979, 91: 539–543.
Meunier F: Prevention of mycoses in immunocompromised patients. Reviews of Infectious Diseases 1987, 9: 408–416.
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weinsdorf D, Winston G, Gilbert G, Buell D: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 1992, 326: 845–851.
Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Winston GH, Islam MZ, Buell DN: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Annals of Internal Medicine 1993, 118: 495–503.
Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, Ricci P, Carotenuto M, Liso V, Nosari AM, Barbui T, Fasola G, Mandelli F, andthe GIMEMA Infection Program: Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Annals of Internal Medicine 1994, 120: 913–918.
Venditti M, De Bernardis F, Micozzi A, Pontieri E, Chirletti P, Cassone A, Martino P: Fluconazole treatment of catheter-related right-sided endocarditis caused byCandida albicans and associated with endophthalmitis and folliculitis. Clinical Infectious Diseases 1992, 14: 422–426.